Drugs / Exebacase
Exebacase
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02439359 | May → Dec 2015 | staphylococcus aureus infection | ContraFect | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT03163446 | May 2017 → Mar 2019 | infective endocarditis, staphylococcus aureus infection | ContraFect | Completed | Missed primary |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT04160468 | Dec 2019 → Sep 2022 | infective endocarditis, staphylococcus aureus infection | ContraFect | Terminated | Missed primary |
| Phase not stated1 trial | ||||||
| — | NCT04597242 | — | COVID-19, methicillin-susceptible staphylococcus aureus infectious disease | ContraFect | No longer available | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Exebacase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04160468 ↗ |
| Known as | CF-301 | “Exebacase (CF-301), a novel, antistaphylococcal lysin (cell wall hydrolase) is the first agent of this class to enter late-stage clinical development (phase 3, NCT04160468) for...” PMID 33910968 ↗ Jun 2021 |
| Known as | Exebacasa | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297925 ↗ |
| Modality | Protein / enzyme biologic | “CF-301 is a lysin and member of a new class of targeted protein-based antimicrobials” NCT03163446 ↗ |
| Route | Intravenous | “Single Intravenous Doses” NCT02439359 ↗ |